Fashion, Home Decor and Health

Defymed Enters Partnership with Semma Therapeutics

PRESS RELEASE - 13-déc.-2016 18:26:41

Defymed enters partnership with Semma Therapeutics Strasbourg, 12 December 2016 - Defymed, a Strasbourg biotech company specialising in the development of bio-artificial organs, announces a strategic collaboration with Semma Therapeutics, an American biotechnology company specialising in the development of cell therapies for the treatment of diabetes, with the goal of developing of an innovative solution for treating type-1 diabetes. The collaboration is aimed at pre-clinical validation of the MAILPAN® bio-artificial pancreas, a device developed by Defymed, in combination with stem-cell derived differentiated insulin-secreting cells developed by Semma Therapeutics. The combination will be evaluated for effectiveness and safety, at first in vitro and then in an animal model. MAILPAN® is a medical device in the form of a pouch made of bio-compatible polymer comprising semi-permeable membranes that allow glucose, nutriments and oxygen to pass through and hence to reach the pancreatic cells contained in the device, delivering the insulin required to regulate the patient’s blood-sugar level. The membranes are impermeable to the immune system and its antibodies, thereby protecting the patient from rejection of the implanted cells. If successful, the collaboration could be an important step in the fight against the global epidemic of diabetes. Diabetes affects more than 420 million people globally, accounting for around $700B in healthcase spending. Type 1 diabetes alone accounts for $14.9 billion in healthcare costs in the U.S., with 1.25M patients on insulin therapy for the disease. In France, it is estimated that 300 000 people have type-1 diabetes, and 2 000 new cases are diagnosed each year. This therapy would potentially offer the patient an unlimited source of insulin-secreting cells, unlike pancreatic islets which are limited by their availibility. Additionally, the device should obviate the need for immuno-suppression treatment, as its membranes as expected to protect the encapsulated cells from any risk of rejection. The patient would no longer have to think about multiple insulin injections each day, as the MAILPAN® combined with Semma’s cells should deliver the right amount of insulin. Defymed’s autonomous and long-lasting medical device thereby is hoped to substantially reduce the complications connected with diabetes. “Semma Therapeutics’ expertise could represent a major new source for cells usable in our medical device,” said Dr Séverine Sigrist, Founding President of Defymed. “It is vital in Defymed’s strategy to validate our medical device with what are currently the most promising cells. We believe the approach developed by Semma is the most advanced worldwide. Everything points to our collaboration being a great success. So I welcome this partnership, which looks very promising indeed!” “Defymed offers one of the most promising options available today in terms of a third party immunoprotective device,” said Robert Millman, CEO of Semma Therapeutics. “We’re excited for the collaboration and look forward to the results.” This exemplary cooperation was recognized as “Best innovative trial design leading to a quicker and better therapeutic outcome” at the MedStartup - Galien Award event on 27 October 2016 in New York. For Defymed, the collaboration follows just six months after concluding a financial agreement for half a million dollars with the JRDF, a global foundation that funds research into treatment for type-1 diabetes. Defymed also has the support and accompaniment of Business France for its development in the United States. The Strasbourg biotech company is keen to become established in this important market in the very near future. About Defymed Defymed, a spin-off of the European centre for the study of diabetes CeeD (Centre Européen d’Étude du Diabète), is a biotechnology company set up in March 2011; it specialises in the design and development of innovative bio-artificial medical devices. Defymed’s initial focus is on developing an application for treating type 1 diabetes. The first product it has designed is MAILPAN©, an implantable bio-artificial pancreas intended to re-establish the normal production of insulin in type 1 diabetics. The MAILPAN© prototype was produced with financial support from the European Commission. The company owns exclusive technology that enables it to produce medical devices for use in other therapeutic applications. Defymed’s strength lies in its network of French and international partners. For more information, please visit www.defymed.com. About Semma Therapeutics Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients. Work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. This breakthrough technology has been exclusively licensed to Semma Therapeutics for the development of a cell-based therapy for diabetes. Ongoing research at Semma Therapeutics is focused on combining these proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. Semma Therapeutics is working to bring new therapeutic options to the clinic and improve the lives of patients with diabetes. The company is headquartered in Cambridge, MA. For more information, visit www.semma-tx.com. COMMUNIQUE DE PRESSE DEFYMED 8 Avenue Dante 67000 Strasbourg - France Tel. +33 (0)3 90 41 04 46 www. defymed .com Further information and visuals available on request from our press service: OXYGEN | Press contacts 2 Rue d’Ingwiller - 67000 Strasbourg [France] Elise Cordier +33 (0)3 67 22 03 25 - elisec@oxygen-rp.com Jérémie Lotz +33 (0)6 11 25 48 05 - jlotz@oxygen-rp.com  


A Look Back: MEDSTARTUP 2016

Elsa RIVE - 22-nov.-2016 23:01:16

  A Look Back: MEDSTARTUP 2016 Business France & The Galien Foundation were pleased with the Medstartup Partnering Day where: NETWORK with +200 Leaders in the EHealth/Pharma/Medtech industrie SOURCE INNOVATION Meet with +50 innovative French Health Tech companies            EXPAND Identify strategic partners to access to the European market     For the second consecutive year, Medstartup was honored to involve inspiring leaders in the industry and fantastic jury composed by Bernard Poussot, Director, Roche Holding, Former Chairman & CEO, Wyeth - Roch DOLIVEUX - Honorary CEO, UCB -Mikael DOLSTEN - Global R&D President, Pfizer -Jean-Pierre GARNIER – Former CEO, GSK -Franz HUMER - Former CEO, Roche -François MAISONROUGE - Senior Managing Director, EvercorePartners -Paul STOFFELS - Chief Scientific Officer, Johnson and Johnson -Elias ZERHOUNI - Global R&D President, Sanofi Key Figures & Facts: +20 New EU-US collaborations per year +65% of C-Levels +550 BtoB Meetings +250  Leaders Every year, MedStartUp Program organized by the Galien Foundation & Business France encourages and rewards transatlantic partnerships in the Healthcare industries. The MedstartUp brought together:   50 highly innovative French companies in the healthcare industry and 200 American leaders in the Pharma/MedTech /Digital Health industries.  Watch the videos of two of the many of the innovative French companies that were at this year’s MedStartUp: Metabolys: Metabolys is developing breakthrough treatments for metabolic diseases with a particular focus on Type 2 Diabetes and NonAlcoholic SteatoHepatitis (NASH)   Protec’Som: Laboratoire Protec’Som is a French medical devices designer whose core jobs are Respiratory Drug Delivery and Protections against allergens. LLTech: In the clinical setting, LLTech seeks to improve clinical practice, patient comfort and hospital economics by accelerating and improving the diagnostic process as well as avoiding repeat procedures.         For further information, visit our website medstartup.galienfoundation.org/wp                


MEDSTARTUP PARTNERING DAY 2016

PRESS - 03-oct.-2016 21:40:13

MEDSTARTUP PARTNERING DAY 2016 Details Start: October 27, 2016 End: October 27, 2016 Event Category: Partner Event Website: medstartup.galienfoundation.org/wp Organizer: Galien Foundation & Business France Phone: 212 400 2168 Website : www.galienfoundation.org Sponsors: Medidata & BIO Registration: Free for Early Birds Venue: Alexandria Center for Life Sciences, 450 E 29th St, New York, NY 10016 Business France & The Galien Foundation are pleased to invite you to the Medstartup Partnering Day to: NETWORK with +250 Leaders in the EHealth/Pharma/Medtech industries SOURCE INNOVATION Meet with +50 innovative French Health Tech companies EXPAND Identify strategic partners to access to the European market       This year we will count with the presence of Bernard Poussot, Director, Roche Holding, Former President & CEO, Wyeth -   Joel Marcus, Founder & CEO, Alexandria Real Estate Equities. - Roch DOLIVEUX - Honorary CEO, UCB -Mikael DOLSTEN - Global R&D President, Pfizer -Jean-Pierre GARNIER – Former CEO, GSK -Franz HUMER - Former CEO, Roche -François MAISONROUGE - Senior Managing Director, EvercorePartners -Paul STOFFELS - Chief Scientific Officer, Johnson and Johnson -Elias ZERHOUNI - Global R&D President, Sanofi Key Figures & Facts: +20 New EU-US collaborations per year +65% of C-Levels +550 BtoB Meetings +250  Leaders Every year, MedStartUp Program organized by the Galien Foundation & Business France encourages and rewards transatlantic partnerships in the Healthcare industries. The MedstartUp will bring together:   55 highly innovative French companies in the healthcare industry and 250 American leaders in the Pharma/MedTech /Digital Health industries. For further information, visit our website medstartup.galienfoundation.org/wp


PRESS: Defymed Receives Support from JDRF to Fight Type 1 Diabetes

PRESS - 13-juil.-2016 00:41:48

Defymed Receives Support from JDRF to Fight Type 1 Diabetes JDRF will contribute up to $500,000 in funds to finance preclinical studies on the MAILPAN ® bioartificial pancreas NEW YORK, July XX 2016 – Defymed, a French biotechnology company specializing in the development of bioartificial organs today announced a partnership with JDRF, the leading global organization funding type 1diabetes (T1D) research. This new investment gives Defymed the opportunity to advance its pre-clinical studies in order to demonstrate the MAILPAN ® immunoprotection properties, safety and function. This is an essential step before beginning the clinical trials on humans. " JDRF is known as the number-one worldwide public foundation fighting type 1 diabetes. We are more than honored to be working with them for the necessary pre-clinical tests before starting the MAILPAN® clinical phase ," explains Dr. Séverine Sigrist, CEO of Defymed. " More than financial support, JRDF brings to us considerable visibility within the U.S. market and also provides strategic support in regards to finding a solution to encapsulating insulin-secreting cells to derive the benefits offered by this therapy to patients suffering from type 1 diabetes." With this support, Defymed will move significantly forward with clinical trials in humans. This new project, scheduled to take up to 24 months, will be conducted simultaneously as other research and development programs currently in progress at Defymed. It will allow Defymed to test the MAILPAN® bioartificial pancreas designed for type 1 diabetics through the preclinical phase in order to: - Strengthen the results on MAILPAN ® ’s immunoprotection properties in combination with insulin-secreting cells. - Confirm collected data on the MAILPAN ®’s functionality and safety , also in combination with insulin-secreting cells. MAILPAN® , a disruptive technology for a better life Almost 25 million people around the world suffer from type 1 diabetes. MAILPAN®, an implantable bioartificial pancreas, is a serious alternative to existing treatments. This medical device is designed to restore normal and continuous insulin production in diabetic patients. Implanted in the abdomen, it takes the shape of a pouch containing insulin-secreting cells. The potential of MAILPAN® will bring numerous advantages in comparison to current treatments (e.g., no anti-rejection drugs in case of pancreatic transplants, absence of multiple insulin injections per day). The bioartificial pancreas’ underlying principle’ is to encapsulate insulin-secreting cells between membranes impermeable to the immune system, but permeable enough for oxygen, nutrients, glucose and insulin. A bioartificial pancreas must fulfill three prerequisite functions: to protect transplanted cells from the patient immune system, to protect the patient from transplanted cells, and to maximize the function of the transplanted cells. The goal of the project is to ensure the function and safety of the medical device, utilizing Defymed’s expertise in the biomaterial and cell transplant , as well as preclinical validation and non-invasive imaging technologies. This strategic step for Defymed confirms the therapeutic interest of the MAILPAN® and will generate preclinical data that is absolutely necessary to build strong regulatory documentation for the MAILPAN® , associated with insulin-secreting cells, which will be necessary to bring it to clinical trials in humans. "JDRF is excited to announce its support of Defymed as it seeks preclinical validation of its MAILPAN® device, a project which is well aligned with JDRF’s Beta Cell Replacement strategy," said Derek Rapp, JDRF president and CEO. "By funding this type of research, we firmly believe we are moving one step closer to our goal of creating a world without type 1 diabetes. Major challenges for Alsatian biotech JRDF support appears as a testament of confidence and represents an important opportunity for Defymed to make significant strides in the biotech world. It will indeed bring more visibility and awareness to French biotech on an international platform. From a strategic standpoint, this financial support will also allow Defymed to pursue its development in Europe but also to prepare its entry in its new target market, the U.S. Defymed has also become a member of the encapsulation consortium, a key JDRF initiative. Its goal is to accelerate the development of a bioartificial pancreas for individuals living with type 1 diabetes. For the complete press release, click the link below    


FRENCH ART OF FURNISHING: 6 companies to keep an eye on at M&O Americas

Geoffroy THAUMIN - 20-avr.-2016 20:35:39

For the very first time, the GEM –the export department of the French furniture industry association– is bringing together six major French furniture players at Maison & Objet Americas. A first step in the US for the GEM, this rendez-vous with French furniture will be followed by many more! The FRENCH ART OF FURNISHING Pavilion will be located booths #1312-1417.  Among the exhibitors: Gautier and its extensive range of stylish and contemporary furniture, but also Maison Montaigne Paris, who represents more than 16 European brands in their Miami showroom. Visitors will also be introduced to Fermob, Sifas and Vlaemynck. Renowned internationally for their premium and luxury outdoors furniture, their designs are created with grace and manufactured to last. Last but not least, Objet de Curiosité will showcase their many wonders, from decorative shells to steampunk lights and from exotic butterflies to mysterious stones. Already successful in France, and for some of them in the US, where their craftsmanship is recognized in niche or mainstream markets, our exhibitors are excited to present their latest designs during the show. For more information about the Pavilion or our exhibitors, please read our online catalogue .


7th French Pavilion at Suppliers’ Day

Pauline MARIE - 07-avr.-2016 00:18:38

  We look forward to greeting you for the launch of the 7th edition of the French Pavilion on Suppliers’ Day. French cosmetics ingredients manufacturers and testing companies will present their latest innovations at the show, on May 10th and 11th in Edison, NJ. BUSINESS FRANCE is proud to introduce this year’s Pavilion’s 10 exhibitors: •ALDIVIA, •AGRIMER, •BIOALTERNATIVES, •CIMAPREM, •DERMSCAN, •EOTECH, •INTERPOLYMER, •MINASOLVE, •PACIFIQUE SUD COSMETIQUE, •TOTAL FLUIDES. For more info about the Pavilion and the companies, please visit our dedicated website . To get the most up to date information, follow us on Twitter @BF_beautycare and on our Facebook!


17 French Eyewear Companies to Keep an Eye on at Vision Expo East

Elodie Fayn - 07-avr.-2016 00:05:52

  Business France is pleased to introduce the fourth International Vision Expo East French Pavilion in New York, in partnership with Lunettes de France, a national umbrella of eyewear trade associations from Paris, Oyonnax and Jura.   The event will take place April 15 th to 17 th 2016 at the Vision Expo East Show. The French Pavilion will showcase 17 of the finest French companies in the eyewear industry offering contemporary and timeless spectacles as well as unique accessories staging the latest trends and designs of the French expertise.   We would like to invite eyewear wholesale retailers, agents and press to visit the French Pavilion booths #6234-6245 & #6135-6141. For more information on the exhibiting French brands and location, please access the catalogue here .   To learn more about the 2016 International Vision Expo, go to www.visionexpoeast.com and for additional information please contact Elodie Fayn . Follow us on Twitter @BF_FashionStyle  and on Pinterest to get the latest news about the event.  


About us
Isabelle Raux - Director of the Fashion, Home Decor and Beauty department at UBIFRANCE North America and her team assists French companies in their search for potential partners, in the US, in the following sectors: Fashion, Luxury and Culture Construction, Decoration, Tourism, Yachting Beauty, Well-Being and Cosmetics   In order to help French companies have a better understanding of the Fashion, Housing, and cosmetics markets in the US, the team organizes individualized missions (market research, list of contacts, B to B meetings) as well as collective missions, such as French Pavilion or walking delegation at the major events in the industry.       

READ MORE

    
    You Buy France 

    

    Rail industry 

   

    Vivapolis  

   

    Healthindustry

   

    Axema

          
   
Facebook
Press area & Media Gallery
List of last comments